Our Science

Our technology platform is based on mixed chimerism, which is the coexistence of two different genotypes of cells―recipient and donor blood and immune cells―in the recipient. A platform that blends two immune systems into one―enabling continued graft acceptance. Our product candidates each comprise a specific composition of different types of donor-derived blood and bone-marrow cells, initially based on breakthrough technologies discovered and developed at Stanford University, and exclusively licensed to us. These patient-specific cellular immunotherapy product candidates include many key cell types such as: CD34⁺ hematopoietic stem cells, and progenitor cells, which produce every type of blood cell in the body, hence the name “stem cell”; and a composition of white blood cells involved in immune responses, including CD3⁺ T cells.